BioPharma Drive: Drug Pricing

FEBRUARY 12, 2024

European venture firm Medicxi built the startup by combining six of its portolio companies, similar to when it merged 10 startups to form Centessa Pharmaceuticals in 2021.

Disease 154

Disease Pharmaceuticals Drugs 154

Drugs.com

JULY 13, 2023

THURSDAY, July 13, 2023 -- More kids in the United States are getting a developmental disability diagnosis, with prevalence close to 9% in 2021, the U.S. Centers for Disease Control and Prevention reports. Among 3- to 17-year-olds, 8.56% have ever.

Disease 189

Disease 189

Drug Target Review

JULY 7, 2023

Approximately three percent of the global population — 240 million people — experience autoantibody diseases, which occur when one’s own body attacks critical organs and tissues. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases.

Disease 98

Disease Immune Response Therapies Treatment 98

Eye on FDA

JANUARY 5, 2022

But before heading into 2022, it is perhaps time to take stock of AdComms and what they did or did not do during 2021. First and foremost is that as noted earlier this year (See August 5, 2021 FDA Adcomms – Is FDA Getting Less Advice? ), there were fewer 2021 meetings held to consider new drug applications than in years gone by.

FDA 76

FDA Clinical Pharmacology Vaccine Production 76

Drug Target Review

JUNE 21, 2023

Most rare diseases are caused by a single gene defect, but severity can vary considerably among patients. Modifier genes can help explain that variability and can alter or even prevent disease onset and progression, making them appealing therapeutic targets. However, the identification of these genes is challenging.

Disease 111

Disease Clinical Trials Therapies Science 111

Drug Discovery Today

FEBRUARY 17, 2021

LONDON, 17 February 2021 – Smiths Detection, a global leader in threat detection and security screening technologies, today reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

Disease 113

Disease Research 113

Drug Discovery Today

JANUARY 25, 2021

OSLO/LONDON, JANUARY 20 2021: EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company today announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions.

Therapies 113

Therapies Disease 113

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. emerged in late 2021. Seventeen of the entire group (10.7%) had “unanticipated monogenic disease risks (uMDRs).” have died of H5N1.

Disease 95

Disease DNA Virus RNA 95

Drug Target Review

OCTOBER 25, 2024

How does precision neuroscience differ from traditional approaches in the treatment of neurodegenerative diseases, and what advantages does it offer? Traditionally, Alzheimer’s disease is diagnosed by clinical examination, medical history and cognitive testing. We believe we are at a breakthrough moment in Alzheimer’s disease research.

Disease 59

Disease Clinical Trials Therapies Science 59

Broad Institute

JUNE 10, 2024

The advance, from the lab of Broad core institute member David Liu , could one day help researchers develop a single gene therapy for diseases such as cystic fibrosis that are caused by one of hundreds or thousands of different mutations in a gene.

DNA 144

DNA Engineering Therapies Disease 144

Drug Target Review

FEBRUARY 8, 2024

3 Moreover, younger CRC patients have been shown to present with more advanced stages of the disease. Gene sequencing The team utilised gene sequencing technology to compare tissue samples taken from 136 young-onset colorectal cancer patients with 140 average-age patients with the disease. 2021 April 22 [2024 February 6]; 13(9):2025.

Disease 105

Disease Research Drugs 105

Olympian Clinical Research

SEPTEMBER 16, 2022

million Americans were living with Alzheimer’s disease in 2021, according to the Centers for Disease Control and Prevention (CDC). Alzheimer’s disease is the seventh leading cause of death in the United States and is a devastating disease that can rob people of their memories and lives.

Disease 52

Disease Clinical Trials Clinical Research Trials 52

Drug Target Review

JULY 4, 2023

In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. For instance, we can compare the data from the 2021 DESTINY gastric cancer trial using the ADC Trastuzumab Deruxtecan with data from a gastric cancer trial in 2004 using the small molecule Irinotecan. Colombo R, Rich JR.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Therapies Pharmaceuticals Clinical Trials 49

KIF1A

MARCH 16, 2024

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. Like hereditary spastic paraplegia, CMT is an umbrella disorder, associated with mutations in over 140 genes, but many diagnosed patients do not know their disease-causing mutation.

Disease 105

Disease Clinical Development Research Treatment 105

biobide

SEPTEMBER 15, 2023

The need to protect crops from pests, disease, and weeds has existed for centuries, with the Roman’s having used ash, crushed cypress leaves and diluted urine to protect their crops. In 2021, the UK government introduced new “Maximum Residue Levels”. Pesticides are a vital tool in safeguarding the world’s food supply.

Regulations 112

Regulations Government Disease Production 112

Drug Target Review

SEPTEMBER 21, 2023

Some report that they believe that if they don’t take the medication, they may develop onchocerciasis-related severe skin diseases and may go blind (river blindness) and would prefer a treatment that does not repeat every year. Need for adulticidal drugs More than 99 percent of countries worldwide has been affected by this disease.

Drugs 105

Drugs Treatment Disease Research 105

DrugBank

AUGUST 9, 2024

Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  reported in 2021. This exponential growth is primarily fueled by the escalating global burden of chronic diseases. trillion by 2028. billion by 2030.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

The Pharma Data

MARCH 16, 2022

His latest work on the development of biosensors has huge potential to benefit patients with certain metabolic diseases.”. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 They could also make it possible to further develop sustainable food systems and achieve ambitious CO2 reduction targets.

Cell Biology 52

Cell Biology Molecular Biology Science Laboratories 52

Chemical Biology and Drug Design

OCTOBER 10, 2023

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. million people worldwide were living with HIV in 2021. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, 38.4 million

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

The Premier Consulting Blog

JUNE 18, 2023

One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

KIF1A

OCTOBER 14, 2023

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. But the opposite relationship is just as important: knowing which diseases are associated with a symptom means earlier diagnosis, and an earlier search for other potential symptoms.

Disease 105

Disease Treatment Research Production 105

The Pharma Data

MARCH 28, 2022

Kerendia ™ (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is approved for the treatment of chronic kidney disease and type 2 diabetes, excluding patients with end-stage renal disease or on dialysis. Food and Drug Administration (FDA) in July 2021. In Japan, an estimated 13.3

Disease 52

Disease Treatment Clinical Trials Trials 52

Broad Institute

MAY 2, 2024

In 2021, Martin competed in the US Olympic trials in a lightweight double, and won the world-renowned Head of the Charles regatta in lightweight single sculls. Liz Martin won first place in lightweight single sculls at the Head of the Charles regatta in 2021. Tell us a bit about your research. What do you like about rowing?

Science 124

Science Medical Schools Disease Hospitals 124

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). of BRT-DA01 in patients with Parkinson’s disease.?. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 The purpose of the?Ph1

Trials 52

Trials Disease Clinical Trials Engineering 52

The Pharma Data

MARCH 16, 2022

(Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease. In June 2021, the U.S.

Disease 52

Disease Clinical Trials Trials Treatment 52

Broad Institute

SEPTEMBER 15, 2023

We apply STACI to analyze the spatio-temporal progression of Alzheimer’s disease and identify the associated nuclear morphometric and coupled gene expression features.

Disease 40

Disease 40

DrugBank

JUNE 27, 2023

Out of the millions of genetic variants present in human populations, GWAS are designed to uncover those associated with specific traits or diseases. 9 Polygenic diseases are much more common, and thousands of genetic variants with very small effects could impact their phenotype.

Disease 98

Disease Treatment Drugs Clinical Trials 98

LifeSciVC

NOVEMBER 17, 2023

This year we start with a deep dive into the biomedical innovation across our industry – “putting the Big back into Big Pharma” with obesity and Alzheimer’s, and the state of play across other disease areas, industry R&D productivity, and the risks facing the sector. As usual, we close with a brief update on Atlas itself.

Science 97

Science Marketing Production Disease 97

New Drug Approvals

SEPTEMBER 29, 2024

gingivalis has been called a risk factor for Alzheimer’s disease ( Kanagasingam et al., gingivalis is associated with cardiovascular disease. In aged dogs with periodontal disease, ninety days of COR388 reduced oral bacterial load and gum pathology ( Arastu-Kapur et al., Cortexyme’s approach is based on the theory that P.

Small Molecule 62

Small Molecule DNA Disease Trials 62

Drug Target Review

AUGUST 9, 2023

Published on bit.bio’s website, this article authored by Dr Tony Oosterveen dives into the close relationship between FTD and ALS with a focus on mechanisms underlying the neuropathology of both diseases. ALS is the most common motor neuron disease and is estimated to affect more than 80,000 people worldwide.

RNA 98

RNA Regulations Disease DNA 98

KIF1A

MAY 4, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. By talking to groups with these mutations, we may identify other diseases whose patients have KIF1A variants. She once worked at SACELLS Biotechnology Co.

Science 116

Science Medical Schools Research RNA 116

SugarCone Biotech

MARCH 24, 2025

Consequently, these drugs have limited ability to keep patients disease-free and limited impact on patient survival. doi: 10.1136/jitc-2021-004348 6. Our goal therefore is to safely improve these types of therapeutics for longer-lasting clinical efficacy. Oncoimmunology 11: 2111904. doi: 10.1080/2162402X.2022.2111904 2022.2111904 3.

Immune Response 64

Immune Response Therapies Treatment Disease 64

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Disease 98

Disease Bioinformatics Medical Schools Research 98

LifeSciVC

APRIL 26, 2024

With just over 60 new biotechs raising their first round of financing, the sector’s company formation activity has slowed 50-60% from its historic peak in 2021. Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories.

DNA 112

DNA Science Marketing Clinical Trials 112

Eye on FDA

JANUARY 26, 2022

That said, the last two letters – the final one of 2021 and the first of 2022 both went to the same company – Lilly. Note: In a prior posting reviewing 2021 regulatory actions, it was stated that FDA issued 5 regulatory action letters for the year.

FDA 108

FDA Production Drugs Disease 108

Drug Target Review

SEPTEMBER 19, 2023

Prior to this European Union Parliament, in 2021, voted for animal testing phase out. Viable in vitro alternatives to animal Models: The European Medicines Agency has launched the new approach methodologies in 2021 promoting the use of animal experiment alternatives in drug discovery and development. The US FDA Modernisation Act 2.0.,

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98